Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 01/21/25 | 8-K | Current report filing |
|
   |
4 |
| 01/21/25 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
14 | |
| 01/16/25 | EFFECT | Notice of Effectiveness |
|
1 | |
| 01/13/25 | POS AM | Post-effective amendment to a registration statement that is not immediately effective upon filing |
|
23 | |
| 12/23/24 | D | Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act. |
|
5 | |
| 12/17/24 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
96 |
| 12/17/24 | 8-K | Current report filing |
|
|
5 |
| 12/10/24 | 8-K | Current report filing |
|
|
94 |
| 12/10/24 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
23 | |
| 12/09/24 | 8-K | Current report filing |
|
|
4 |
